

## Key findings

- Work ability is impaired in the majority of axSpA patients.
- Work ability is associated with age, disease activity, function, mental health, and predominantly physically demanding work.

Uta Kiltz<sup>1,2</sup>, Anja Weiß<sup>3</sup>, Daniel Bestler<sup>4</sup>, Anja Strangfeld<sup>3,5</sup>, Xenofon Baraliakos<sup>1,2</sup>, Anne C. Regierer<sup>3</sup>

<sup>1</sup>Rheumazentrum Ruhrgebiet, Herne, Germany, <sup>2</sup>Ruhr University Bochum, Germany, <sup>3</sup>Deutsches Rheuma-Forschungszentrum Berlin, Germany, <sup>4</sup>Praxis, Erfurt, Germany, <sup>5</sup>Charité – Universitätsmedizin Berlin, Germany

German Rheumatism Research Centre,  
Registry Research in Rheumatology

## Objectives

- To evaluate the frequency and severity of impairment in ability to work
- To assess factors associated with work ability

	Poor n=334 (28%)	Moderate n=515 (44%)	Good & excellent n=336 (28%)	Total n=1,185
Age in years, mean	45	42	39	42
Female, %	47	46	40	45
Symptom duration in years, mean	10	11	9	10
BASDAI, mean	5.7	4.6	3.3	4.6
ASDAS, mean	3.2	2.8	2.2	2.7
BASFI, mean	4.9	3.5	1.9	3.4
ASAS-HI, mean	9.3	6.6	3.6	6.5
WHO-5 moderate/severe, %	49	26	7	27
sick leave during last 6 months, %	71	40	14	42
Days on sick leave last 6 months, mean	44	22	14	31




Figure 1: WAI score separated by sex, by symptom duration  $\leq 2$ / $> 2$  years, and by work demand (mentally [m], physically [p] or equally [both] demanding work).

## WAI

### Associated with:

- BASDAI
- BASFI
- WHO-5 score
- Age
- Patient's work

### Not associated with:

- Sex
- Symptom duration
- BMI

## Patients & Methods

- axSpA patients included in RABBIT-SpA
- Age 18-65
- Work ability index (WAI)
- Cross-sectional
- Multiple linear regression analysis

## Results

Of 1,185 patients mean WAI score was 32 corresponding to a moderate work ability. Disease activity parameter and PROs were worse according to impaired work ability.




Figure 2: Scatter plot showing WAI vs. BASFI with different colours for the WHO-5 values.

Funding: RABBIT-SpA is currently supported by a joint, unconditional grant from AbbVie, Amgen, Biocon, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer and UCB.

We thank all participating patients and rheumatologists!

